Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

856P - A comparison of the burden of leukemia amongst European Union 15+ countries, 1990-2019

Date

16 Sep 2021

Session

ePoster Display

Topics

Cancer Prevention

Tumour Site

Leukaemias

Presenters

Chinmay Jani

Citation

Annals of Oncology (2021) 32 (suppl_5): S773-S785. 10.1016/annonc/annonc676

Authors

C.T. Jani1, H. Singh2, O. Al Omari1, G. hanbury3, A. Kelaiya4, J. Shalhoub5, D. Marshall6, L. Weissmann7, J. Salciccioli8

Author affiliations

  • 1 Internal Medicine, Mount Auburn Hospital - Harvard Medical School, 02138 - Cambridge/US
  • 2 Pulmonary And Critical Care, MEdical College of wisconsin, milwaukee/US
  • 3 Internal Medicine, Imperial College Healthcare NHS Trust, London/GB
  • 4 Internal Medicine, B.J. Medical College, Ahmedabad/IN
  • 5 Academic Section Of Vascular Surgery, Department Of Surgery And Cancer, Imperial College London, UK and Imperial Vascular Unit, Imperial College Healthcare NHS Trust, London/GB
  • 6 Internal Medicine, National Heart and Lung Institute, Imperial College, London/GB
  • 7 Division Of Hematology - Oncology, Department Of Internal Medicine, Mount Auburn Hospital - Harvard Medical School, 02138 - Cambridge/US
  • 8 Pulmonary And Critical Care, Brigham and Women's Hospital-Harvard Medical School, Boston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 856P

Background

Leukemia is the tenth most common cause of cancer related deaths. In 2018, there were a total of 437,000 estimated new cases and 309,000 deaths of leukemia worldwide. The objective of this study is to observe the trends in mortality, incidence and disability-adjusted life years (DALYs) from all types of leukemia between 1990-2019 in European Union (EU) 15+ nations.

Methods

We extracted the data from the Global Burden of Disease Study database based on the International Classification of Diseases versions 10 and 9. Age-standardized incidence rates (ASIR), age-standardized mortality rates (ASMR), and DALYs were extracted for individual EU15+ countries per sex for each of the years 1990-2019, inclusive, and mortality-to-incidence indices (MII) were computed. All indices were reported per 100,000 population.

Results

ASIRs increased in 17/19 countries for males and 14/19 countries for females. The largest increase was in Germany (+56.4%) for males, and in Austria for females (+48.8%). All countries observed decreasing ASMRs for females and males except for males in the Netherlands (+1.9%). The greatest decreases were seen in Denmark for both males (-37.4%) and females (-38.9%). For both sexes, the MIRs decreased in all countries. The largest reductions were found in Ireland for males (-51.1%) and females (-54.7%). DALYs were decreased in all the countries for both genders. Denmark had the highest decreases for both males (-49.3%) and females (-50.1%). In 2019, Germany had the highest ASIR for males (26.7) and females (17.7). USA had the highest MIR for both males (0.57) and females (0.56). Greece showed the highest ASMR for males (8.2) and females (5.2) as well as DALY for males (205.1) and females (136.6).

Conclusions

Although incidence of leukemia is increasing in the majority of EU15+ countries, mortality, MIR as well as DALYs have shown a downwards trend. Possible explanations for the increases in incidence could relate to ageing populations, changes in leukemia diagnosis criteria (lowering the blast count for acute myeloblastic leukemia) in 2001, and increases in chemoradiation-related leukemias. ASMRs, MIRs and DALYs have consistently decreased possibly reflecting effective new treatments modalities especially for chronic lymphocytic leukemia.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.